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260.000 atherosclerosis-related hospitalizations occurred
in Italy. There is evidence that Amlodipine treatment is
effective in reducing the health burden of atherosclerosis
and the objective of this analysis is to assess the pharma-
coeconomic proﬁle of Amlodipine in atherosclerotic
disease and in the Italian scenario. METHODS: Alterna-
tives: standard care plus Amlodipine besylate treatment
vs standard care alone in patients with CAD identiﬁed by
angiography in Italy. Perspective: National Health Service
(NHS). Technique: cost-effectiveness analysis on 2 hypo-
thetical cohorts of 1000 subjects; an incremental cost 
per patient free for events has been calculated. Time: 36
months. All effects and costs were discounted with an
annual rate of 5%. Costs: drugs and direct medical costs
quantiﬁed by using NHS tariffs expressed in €2002.
Effects: measured through the results from the PREVENT
study (Pitt B et al, 2000): i.e. fatal acute myocardial
infarction (AMI) or not, fatal stroke or not, congestive
heart failure, unstable angina, CABG and PTCA.
RESULTS: Treating the hypotethical cohort of 1000 sub-
jects with Amlodipine resulted in a total cost of
€2,896,345 (€1,267,472 for pharmacological treatment
and €1,628,873 for treating 355 events). Treating the
hypotethical cohort of 1000 subjects with placebo
resulted in a total cost of €2,643,732 to follow 547
events. The treatment with Amlodipine was superior
regarding the development of any ﬁrst event (206 with
Amlodipine and 284 with placebo) and the incremental
cost per patient free for events was €3,235. CONCLU-
SIONS: The results indicate that Amlodipine therapy is
more effective and more costly than placebo and that a
drug investment with Amlodipine leads to a signiﬁcant
reduction of the health burden of atherosclerotic disease.
The incremental health beneﬁt can be obtained at an
affordable cost.
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OBJECTIVE: The AVERT study (Atorvastatin versus
Revascularization Treatment) showed the beneﬁts of the
aggressive treatment with Atorvastin (ATV) 80mg/day in
reducing the incidence of ischemic events. The objective
of this analysis was to compare the associated costs of
ATV-80mg vs Percutaneous Coronary Intervention (PCI)
using unit costs from Spain. METHODS: This Econom-
ical Evaluation (EE) compared the total expected cost and
cost-effectiveness of treatment with ATV-80mg daily
versus PCI, for 18 months. 341 patients (pts) with stable
coronary artery disease were randomized to receive
medical treatment with ATV-80mg/day (164pts), or 
to undergo the recommended PCI followed by usual 
care including lipid-lowering treatments (177pts). The
primary outcome was ischemic cardiovascular events. 
EE has been performed from a 3rd payer perspective (the
National Health Services, with 2001 costs). The cost of
ATV-80mg used was twice ATV-40mg (€2.64 per tablet)
currently marketed. RESULTS: The 164pts included in
ATV-group suffered 36 events (22pts) with hospitaliza-
tion and the 177pts in PCI-group, 61 events (37pts). The
Total Cost in ATV-group was €378,853.31: sum of Ator-
vastatin-80mg Treatment Total Cost: 233,798,40€and all
Inpatient Events Cost: €145,054.91 (in this amount is
included 18 PCIs as event: €76,676.40). The Total Cost
in PCI-group was €1,075,647.82: sum of PCI Total Cost:
€753,984.60, all Inpatient Events Cost €280,504.42
(included 21 PCIs as event in this group: €89,455.80),
and Concomitant Lipid-lowering Treatment Cost:
€41,158.80. Therefore the Cost Per Event in ATV-group
was €2,310.08 and 6,077.11€ in PCI-group, with a dif-
ference of €3,767.03 per event more in the PCI-group.
The Incremental Cost Per Event Avoided was 
-€30,107.16 in the ATV-group. CONCLUSIONS: In
low-risk patients with stable coronary artery disease,
aggressive lipid-lowering therapy with ATV-80mg/day is
at least as effective as angioplasty, after 18 months of
follow-up, and it is cost-saving to the National Health
Services.
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OBJECTIVE: To compare the economic consequences of
antihypertensive treatment with perindopril (1 ¥ 4mg)
and enalapril (2 ¥ 10mg). METHODS: The clinical, epi-
demiological and economic data were derived from a sci-
entiﬁc project conducted in the whole of Poland among
GPs, and concerned 438 patients treated in mono-therapy
within the last year. Calculations were made from the
societal perspective and the retrospective approach was
applied. The direct medical costs of: pharmacological
treatment, doctors’ consultations, hospitalisation, labora-
tory and diagnostic tests were identiﬁed and calculated.
Indirect costs were also assessed by the capital cost
method. Effectiveness was measured by the percentage of
the patients with appropriate blood pressure control
according to the ﬁrst deﬁnition (BP£140/90mmHg) and
the second deﬁnition, (BP < 140/90mmHg), consistent
with JNC VI guidelines. RESULTS: Effectiveness, mea-
sured according to the ﬁrst deﬁnition was 52,45% in the
perindopril group and 41,03% in the enalapril group.
